Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
Bleichroeder LP and related reporting persons filed a Schedule 13G regarding holdings in SINTX Technologies Inc. They report beneficial ownership of 647,513 common shares, representing 9.99% of the outstanding common stock, including both shares held and shares issuable under warrants subject to a beneficial ownership cap.
The position consists of 523,013 common shares and 124,500 shares issuable upon exercise of warrants. The warrants include a 9.99% beneficial ownership limitation that restricts further exercises. Absent this limit, Bleichroeder indicates it would be deemed to beneficially own 1,569,039 shares, or 21.19% of SINTX’s outstanding common stock.
SINTX Technologies, Inc. reports that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity for continued listing. Based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, Nasdaq’s Listing Qualifications Staff noted stockholders’ equity of $4,830,000 (approximately $4.83 million) and confirmed that the prior deficiency matter is now closed.
The company states that it remains focused on commercializing its silicon nitride-based medical products, expanding its distribution network, and developing strategic partnerships to support future revenue growth, while working to maintain compliance with Nasdaq’s continued listing requirements.
SINTX Technologies, Inc. is registering for resale up to 1,268,135 shares of common stock issuable upon exercise of new warrants held by a single selling stockholder under a June 29, 2026 letter agreement. These are secondary sales; the selling stockholder receives all proceeds from any share resales.
If the New Warrants are exercised for cash at $2.14 per share, SINTX could receive up to approximately $2.7 million, planned for working capital and general corporate purposes. Shares outstanding would rise from 6,664,534 to 7,932,669 if all New Warrants are exercised, in addition to a sizable existing warrant and preferred overhang.
The company highlights risks that warrant exercises and sales may pressure the stock price and increase dilution, and notes a Nasdaq notice received in May 2026 for not meeting the $2.5 million minimum stockholders’ equity requirement, with stockholders’ equity of $904,000. Failure to regain compliance could lead to delisting, reducing liquidity and potentially impairing future capital-raising.
SINTX Technologies provided a mid‑year 2026 update tied to its June 30, 2026 quarter. The company advanced commercialization of its FDA‑cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, launching a Limited Use Release and building an initial network of twelve independent orthopedic distributors focused on foot and ankle surgery. Management highlighted expanding industrial ceramics activity, including approximately $3.2 million in new industrial purchase orders, with related revenue expected to begin in the third quarter of 2026 subject to delivery and revenue‑recognition requirements.
The company issued a revenue outlook of about $900,000–$1.1 million for the third quarter of 2026 and $1.0–$1.3 million for the fourth quarter, stressing that these expectations are highly uncertain and depend on production, shipment timing, customer acceptance and other factors. SINTX completed construction of a 3D‑printing facility to support future SiNERGY™ patient‑specific silicon nitride/PEEK implants and received an additional 12‑month period to access roughly $745,000 remaining on a $1.97 million NIH grant for porous silicon nitride/PEEK spinal fusion implants.
During the second quarter, SINTX raised approximately $5.0 million in gross proceeds through a private placement and sales under its at‑the‑market equity program and noted remaining ATM capacity. Management emphasized capital‑allocation and cost‑optimization efforts but acknowledged limited liquidity, ongoing operating losses, dependence on additional financing and explicitly referenced substantial doubt regarding the company’s ability to continue as a going concern.
SINTX Technologies reported higher revenue but continued losses for the quarter ended June 30, 2026. Total revenue rose to $452 thousand for the quarter and $832 thousand for the first half of 2026, driven mainly by product revenue growth and initial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System, along with OEM industrial products.
Despite this, the company remains loss-making, posting a net loss of $2.7 million for the quarter and $5.5 million year-to-date. Operating expenses increased to $3.2 million for the quarter as SINTX shifted overhead from R&D into general and administrative and expanded sales and marketing to support commercialization. Cash and cash equivalents were $3.6 million at June 30, 2026, after using $5.3 million in operating cash in the first half and raising capital through a $4.5 million private placement and $1.3 million of ATM sales.
Management explicitly states that substantial doubt exists about SINTX’s ability to continue as a going concern over the next 12 months, even after divesting non-core operations, subleasing the Armor facility, and accessing equity financing. The company’s strategy centers on leveraging its silicon nitride technology in higher-growth medical markets while maintaining its industrial ceramics business as a revenue base.
SINTX Technologies, Inc. announced that it has engaged Southern Metrics Consulting, led by medical technology executive and SINTX board member Chris Lyons, to establish and manage a new Strategic Opportunity Management Program focused on enhancing stockholder value.
The program is intended to create a disciplined, proactive framework for identifying, evaluating, prioritizing, and managing strategic opportunities that support SINTX’s long-term growth strategy. Working with executive management and the board, Southern Metrics will assess options including commercial partnerships, licensing, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. The company notes that the engagement does not indicate any specific transaction is pending and there is no assurance any opportunity will be identified, pursued, completed, or successful.
SINTX Technologies entered a letter agreement with MedTech Ceramics to clean up prior warrant-related share arrangements and modify its capital structure. The company will release 255,267 common shares from abeyance and convert the remaining 251,987 abeyance shares into a pre-funded warrant for the same number of shares, all for consideration already paid in a September 2025 transaction. An existing warrant to purchase 760,881 shares will be cancelled and replaced with a new warrant to buy 1,268,135 shares at $2.14 per share. SINTX plans to file a resale registration statement for the shares underlying the new warrant within 45 days and notes that these steps are intended to help its efforts to improve stockholders’ equity, while actual equity levels will continue to depend on its broader financial condition.
SINTX Technologies, Inc. is registering the resale of 5,819,323 shares of common stock issued in a private placement on June 2, 2026. The shares include 1,882,846 Common Shares, 3,765,692 Warrant Shares (Class A, Class B and Placement Agent Warrant Shares), and 78,212 Compensation Shares.
The company will not receive proceeds from resales by the selling stockholders; however, if the registered Warrants are exercised for cash the company would receive up to approximately $8.3 million. Shares outstanding were 6,357,630 as of June 22, 2026, rising to 10,215,895 assuming exercise of all Warrants.
The prospectus discloses Nasdaq noncompliance: stockholders’ equity of $904,000 as reported for the quarter ended March 31, 2026, and a July 6, 2026 deadline to submit a plan to regain compliance.